Journal Mobile Options
Table of Contents
Vol. 78, No. 2, 2009
Issue release date: March 2009

Reliability and Validity of the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire

Fava M. · Iosifescu D.V. · Pedrelli P. · Baer L.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Background: We have recently developed the Massachusetts General Hospital Cognitive and Physical Functioning Questionnaire (CPFQ), a brief scale to measure cognitive and executive dysfunction in mood and anxiety disorders, and we here report on its reliability and validity. Methods: The internal consistency of the CPFQ was assessed by computing Cronbach’s coefficient α based upon the average intercorrelation of the 7 items of the CPFQ in a sample of depressed outpatients and by factor analyzing data from the same sample to confirm that the scale is unifactorial and measuring a single construct. Test-retest reliability of the CPFQ was assessed in a different sample of depressed outpatients by computing Pearson’s correlation coefficient between pretreatment screening scores and pretreatment baseline scores. Sensitivity to change of the CPFQ was assessed by computing the dependent t test for the subjects in the active treatment condition in the second sample of depressed outpatients. Finally, convergent validity for the CPFQ was assessed in two different ways. Results: We found that the CPFQ is a unifactorial scale, with strong internal consistency. It has good temporal stability as indicated by high test-retest reliability. The CPFQ was also found to be sensitive to change with treatment and displayed convergent validity by significant correlations with other measures of sleepiness, fatigue, apathy and neuropsychological functioning. Although, as expected, the CPFQ was significantly correlated with a measure of depression, the moderate correlation (r ∼ 0.30) indicates that the CPFQ is measuring a different construct. Conclusion: In summary, the CPFQ is a unifactorial scale, with strong internal consistency, good temporal stability and sensitivity to change with treatment. Further studies will be needed to assess the validity and reliability of this instrument in other psychiatric and neuropsychiatric conditions associated with cognitive dysfunction.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Addington AM, Gallo JJ, Ford DE, Eaton WW: Epidemiology of unexplained fatigue and major depression in the community: the Baltimore ECA follow-up, 1981–1994. Psychol Med 2001;31:1037–1044.
  2. Cohen RM, Weingartner H, Smallberg SA, Pickar D, Murphy DL: Effort and cognition in depression. Arch Gen Psychiatry 1982;39:593–597.
  3. Elliot R, Sahakian BJ, McKay AP, Herrod JJ, Robbins TW, Paykel ES: Neuropsychological impairments in unipolar depression: the influence of perceived failure on subsequent performance. Psychol Med 1996;26:975–989.
  4. Fava M: Symptoms of fatigue and cognitive/executive dysfunction in major depressive disorder before and after antidepressant treatment. J Clin Psychiatry 2003;64(suppl 14):30–34.

    External Resources

  5. Clark LD, Iversen SD, Goodwin G: A neuropsychological investigation of prefrontal cortex involvement in acute mania. Am J Psychiatry 2001;158:1605–1611.
  6. Martinez-Aran A, Vieta E, Reinares M, Colom F, Torrent C, Sanchez-Moreno J, Benabarre A, Goikolea JM, Comes M, Salamero M: Cognitive function across manic or hypomanic, depressed, and euthymic states in bipolar disorder. Am J Psychiatry 2004;161:262–270.
  7. Reischies FM, Neu P: Comorbidity of mild cognitive disorder and depression – a neuropsychological analysis. Eur Arch Psychiatry Clin Neurosci 2000;250:186–189.
  8. Fava M, Graves L, Benazzi F, Scalia MJ, Iosifescu DV, Alpert JE, Papakostas GI: Prevalence of cognitive and physical adverse events during long-term antidepressant treatment. J Clin Psychiatry 2006;67:1754–1759.
  9. Ferrier IN, Stanton BR, Kelly TP, Scott J: Neuropsychological function in euthymic patients with bipolar disorder. Br J Psychiatry 1999;175:246–251.
  10. Honig A, Arts BM, Ponds RW, Riedel WJ: Lithium induced cognitive side-effects in bipolar disorder: a qualitative analysis and implications for daily practice. Int Clin Psychopharmacol 1999;14:167–171.
  11. McKay AP, Tarbuck AF, Shapleske J, McKenna PJ: Neuropsychological function in manic-depressive psychosis. Evidence for persistent deficits in patients with chronic, severe illness. Br J Psychiatry 1995;167:51–57.
  12. van Gorp WG, Altshuler L, Theberge DC, Mintz J: Declarative and procedural memory in bipolar disorder. Biol Psychiatry 1999;46:525–531.
  13. Rubinsztein JS, Michael A, Paykel ES, Sahakian BJ: Cognitive impairment in remission in bipolar affective disorder. Psychol Med 2000;30:1025–1036.
  14. Richards PM, Ruff RM: Motivational effects on neuropsychological functioning: comparison of depressed versus nondepressed individuals. J Consult Clin Psychol 1989;57:396–402.
  15. Ilsley JE, Moffoot AP, O’Carroll RE: An analysis of memory dysfunction in major depression. J Affect Disord 1995;35:1–9.
  16. Clark L, Iversen SD, Goodwin GM: Sustained attention deficit in bipolar disorder. Br J Psychiatry 2002;180:313–319.
  17. Cavanagh JTO, Van Beck M, Muir W, Blackwood DHR: Case-control study of neurocognitive function in euthymic patients with bipolar disorder: an association with mania. Br J Psychiatry 2002;180:320–326.
  18. Deckersbach T, Savage CR, Reilly-Harrington N, Clark L, Sachs G, Rauch SL: Episodic memory impairment in bipolar disorder and obsessive-compulsive disorder: the role of memory strategies. Bipolar Disord 2004;6:233–244.
  19. Atre-Vaidya N, Taylor MA, Seidenberg M, Reed R, Perrine A, Glick-Oberwise F: Cognitive deficits, psychopathology, and psychosocial functioning in bipolar mood disorder. Neuropsychiatry Neuropsychol Behav Neurol 1998;11:120–126.
  20. Mendoza T, Wang XS, Cleeland CS, Morrissey M, Johnson BA, Wendt JK, Huber SL: The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory. Cancer 1999;85:1186–1196.
  21. Johns MW: A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale. Sleep 1991;14:540–545.
  22. Connors CK: The Continuous Performance Test (CPT): use as a diagnostic tool and measure of treatment outcome. Annu Meet Am Psychol Assoc, Los Angeles, 1994.
  23. Marin RS, Biedrzycki RC, Firinciogullari S: Reliability and validity of the Apathy Evaluation Scale. Psychiatry Res 1991;38:143–162.
  24. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56–62.
  25. Hamilton MA: The assessment of anxiety states by rating. Br J Med Psychol 1959;32:50–55.
  26. Fava M, Thase ME, Debattista C: A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepiness. J Clin Psychiatry 2005;66:85–93.
  27. Fava M, Asnis G, Shrivastava R, Lydiard, RB, Bastani B, Sheehan D, Roth T: Improved insomnia symptoms and next-day functioning in patients with comorbid insomnia and generalized anxiety disorder following concomitant zolpidem extended-release 12.5 mg and escitalopram 10 mg treatment. ACNP Annu Meet, Boca Raton, 2007.
  28. Stata Corp: Intercooled Stata 8.2. College Station, Stata Corp, 2005.
  29. SPSS Inc: SPSS Version 14.0. Chicago, SPSS Inc, 2005.
  30. Cronbach LJ: Coefficient alpha and the internal structure of tests. Psychometrika 1951;16:297–333.
  31. Gorsuch RL: Factor Analysis, ed 2. Hillsdale, Erlbaum, 1983.
  32. Rush AJ, Kraemer HC, Sackeim HA, Fava M, Trivedi MH, Frank E, Ninan PT, Thase ME, Gelenberg AJ, Kupfer DJ, Regier DA, Rosenbaum JF, Ray O, Schatzberg AF, ACNP Task Force: Report by the ACNP Task Force on response and remission in major depressive disorder. Neuropsychopharmacology 2006;31:1841–1853.
  33. Iosifescu DV, Moore M, Deckersbach T, Nierenberg A, Fava M, Gironde S, Renshaw PF, Sachs GS: Galantamine-CR for cognitive dysfunction in bipolar disorder: efficacy and biological correlates. Am Psychiatr Assoc 159th Annu Meet, Toronto, 2006.
  34. Fava GA, Tomba E, Grandi S: The road to recovery from depression – don’t drive today with yesterday’s map. Psychother Psychosom 2007;76:260–265.
  35. Benazzi F: Is there a continuity between bipolar and depressive disorders? Psychother Psychosom 2007;76:70–76.
  36. De Figuereido JM: Demoralization and psychotherapy: a tribute to Jerome D. Frank, MD, PhD (1909–2005). Psychother Psychosom 2007;76:129–133.
  37. Colom F, Vieta E: Sudden glory revisited: cognitive contents of hypomania. Psychother Psychosom 2007;76:278–288.
  38. Honkalampi K, Hintikka J, Koivumaa-Honkanen H, Antikainen R, Haatainen K, Viinamaki H: Long-term alexithymic features indicate poor recovery from depression and psychopathology: a six-year follow-up. Psychother Psychosom 2007;76:312–314.
  39. Hossain NK, Irvine J, Ritvo P, Driver HS, Shapiro CM: Evaluation and treatment of sleep complaints: patients’ subjective responses. Psychother Psychosom 2007;76:395–399.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50